Skip to main content

isotretinoin

Generic: ISOTRETINOIN·Brand: ABSORICA, ABSORICA LD, ACCUTANE, AMNESTEEM, Accutane, CLARAVIS, ISOTRETINOIN, MYORISAN, SOTRET, ZENATANE

isotretinoin: developed by 1 company · 6 clinical trials tracked.

isotretinoin evidence translation

What we can confirm

What it means

Source-backed records connect isotretinoin to DERM; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could isotretinoin → DERM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 3 study sponsors
Development Pipeline (1)
CompanyPhase
Journey Medical Corp (DERM)
Severe recalcitrant nodular acne
Approved
Clinical Trials (6)

A Phase 2 Study of Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

NCT07629167·Phase 2
Not yet recruiting

Primary endpoint: Proportion of Participants who experienced acneiform rash

InterventionalRandomizedopen50 targetStarted 2026-08Completion 2030-031 site · United StatesUniversity of California, San Francisco

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

NCT06942039·Early Phase 1·AIM
Recruiting

Primary endpoint: To determine the feasibility of adding intrathecal (IT) topotecan and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.

Interventionalopen15 targetStarted 2025-09Completion 2032-1212 sites · CanadaC17 Council

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

NCT06172296·Phase 3·BDTX
Recruiting

Primary endpoint: Event free survival (EFS)

InterventionalRandomizedopen478 targetStarted 2024-04Completion 2029-1250 sites · United StatesNational Cancer Institute (NCI)

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

NCT03126916·Phase 3
Recruiting

Primary endpoint: Event free survival (EFS) (Arm A, B, D, and E)

InterventionalRandomizedopen750 targetStarted 2018-05Completion 2030-0950 sites · United StatesChildren's Oncology Group

Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study

NCT03033303·Phase 2
Completed

Primary endpoint: relapse-free survival (RFS)

Interventionalopen59 enrolledStarted 2017-01Completion 2025-091 site · United StatesMemorial Sloan Kettering Cancer Center

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

NCT00392327·Phase 3·CGON
Completed

Primary endpoint: Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma

InterventionalRandomizedopen379 enrolledStarted 2007-05Completion 2026-0350 sites · United StatesChildren's Oncology Group

Frequently asked questions

Who is developing isotretinoin?

isotretinoin is being developed by Journey Medical Corp.

How many clinical trials involve isotretinoin?

BioSniper tracks 6 clinical trials involving isotretinoin.